Advancement of the relationship ERCC1 and platinum resistance in digestive system malignant tumors

Abstract

Abstract: Due to the high incidence and mortality of digestivesy stem malignant tumor, so it is of great significance to make further research for digestive tract tumor.Platinum drugs, one of the traditional drugs which is used for the chemo therapy for digestive system tumor, which has been extensively applied to the chemotherapy for malignant tumor.However, the resistance to the drug s exerts a serious influence on its curative effect.At present, it is believed that the nucleotide excision repair (NER) constitutes one of the most important mechanisms which results in the resistance to platinum drugs, mainly because it causes the twi sting of DNA helix by removing large numbers of platinum compounds. The nucleotide excision repair cross complementation group 1(ERCC1) plays an important role in the process of N ER.The different expression of ERCC1 in peripheral blood and tumor tissue of patients with digestive sysem tumor has a close connect ion with therapeutic effect of the platinum-containing chemotherapy.This article aims to provide an overview of the relation between the ERCC1 research development and the curative effect of cisplatin chemotherapy for digestive system tumor.

Key words: Chemo therapy, Platinu, Drugresi stance, Nucleotide excision repair, Tumor

CLC Number:

R735

LI Xiao-qiu, HU Bing. Advancement of the relationship ERCC1 and platinum resistance in digestive system malignant tumors[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 116-120.

References

[1] Zamble DB, Llppard SJ. Cisplatin and DNA repair in cancer chemotherapy[J]. Trends Biochem Sci, 1995, 20(10): 435-439.
[2] Ahaha R, Llang X, Yu JJ, et al. Excision repair cross complementing-group 1: gene expression and platinum resistance[J]. Int J Mo l Med, 2004, 14(6): 959-970.
[3] Bermstein C, Bernstein H, Payne CM, et al. DNA repair/proapoptotic dual-role proteins in five major DNA repair pathway s: fail-safe pro tection against carcinogenesis[J]. Mutr Res, 2002, 5(11): 145-178.
[4] Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinatingag ents[J]. Cancer Treat Rev, 2007, 33(1): 9-14.
[5] Gazdar AF. DNA repair and survival in lung cancerthe two face s of Janus[J]. N Engl Med, 2007, 356(8): 771-776.
[6] Sugakawa K, Ng JMY, Matsutani C, et al. Xero derma pigmento sum group Cprotein complex is the initiator of global gene nucleo tide excision repair[J]. Mo LCell, 1998, 2(2): 223-232.
[7] 黄强, 陈忠平, 兰青, 等. 胶质瘤[M]. 中国科学技术出版社, 2000: 400-401.
[8] Gillet LC, Schrer OD. Molecular mechanisms of mamma liang lobal genome nucleotide excision repair [J]. Chem Rev, 2006, 106(2): 253-258.
[9] Britten RA, Liu D, Tessier A, et al. ERCC1 expression as a molecular marker of cisplatinr esistance in human cervical tumor cells [J]. Int J Cancer, 2000, 89(5): 453-458.
[10] Wilson MD, Ruttan CC, Koop BF, et al. ERCC1: a corn-pa rative genomic per spective[J]. Envir on Mol Mutagen, 2001, 38(2/3): 209-2l5.
[11] Kiyohara C, Yo shimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: A meta-analysis[J]. Int J Med Sci, 2007, 4(2): 59-71.
[12] Li YC, Gu SH, Wu QH, et al. No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis[J]. Eur J Hum Genet,2007, 15(9): 967-973.
[13] Wei Q, Frazier M L, Levin B. DNA repair: a double 2edged sword[J]. J Natl Cancer Inst, 2000, 92(6): 440-441.
[14] Joshi MB, Shirota Y, Danerberg KD, et al. High gene expression of TS1, GS TP1 and ERCC1 are risk factors for survival in patients treated with trimodality the rapy for esophageal cacer[J]. Clin Cancer Res, 2005, 11(8): 2215-2221.
[15] Brabender J, Vallbohmer D, Grimminger P, et al. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus[J]. J Gastr ointest Surg, 2008, 12(11): 1815-1821.
[16] Warnecke-Eberz U, Vallbö hmer D, Alakus H, et al. ERCC1 and XRCC1 Gene Polymorphisms 17 Predict response to neoadjuvant radio chemo therapy in esophageal cancer[J]. Predict response to neo adjuv ant radio chemo therapy in esophageal cancer[J]. J Ga strointest Surg, 2009, 13(8): 1411-1421.
[17] Kwon HC, Roh M S, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathioneS-transfe rase Plfor 5-fluo rouracil/oxaliplatin chemo therapy in advanced gastric cancer[J]. Ann Oncol, 2007, 18(3): 504-509.
[18] Wei J, Zou Z, Qian X, et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen [J]. Br J Cancer, 2008, 9(8): 1398-1402.
[19] 黄朝晖, 华东, 李莉华, 等, ERCC1 m RNA 表达及基因多态性对胃癌辅助化疗预后的影响[J]. 南京医科大学学报:自然科学版, 2008, 28(4): 453-456.
[20] Chang PM, Tzeng CH, Chen PM, et al. ERCC1 co do n 118 CT polymorphism associated ERCC1 expression and outcome of FOLFOX-4 with treatment in Asian patients with metastatic colorectal carcinoma20] Chang PM, Tzeng CH, Chen PM, et al. ERCC1 codon 118 CT polymorphism associated ERCC1 expression and outcome of FOLFOX-4 with treatment in Asian patients with metastatic colorectal carcinoma[J]. Cancer Sci, 2009, 100(2): 278-283.
[21] Iqbal S, Lenz H J. Molecular predictors of treatment and outcome in co lo rectal cancer[J]. Curr Gastr oenterol Rep, 2003, 5(5): 399-405.
[22] Kamikozur u H, Kuramochi H, Hayashi K, et al. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemo therapy[J]. Int J Onco l, 2008, 32(5): 1091-1096.